Loading…
Reported covered position: n/a
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via NOVEL STRATEGIES (FKA) PRISM GROUP
2026 · third_quarter · Q3
Matters pertaining to strengthening regulatory procedures at the Food and Drug Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via NOVEL STRATEGIES (FKA) PRISM GROUP
2026 · third_quarter · RR
Source: Senate LDA
Modernizing clinical trials and the regulatory process at the Food and Drug Administration
GENEVANT SCIENCES, INC. via NOVEL STRATEGIES (FKA) PRISM GROUP
2026 · third_quarter · Q3
Matters pertaining to patent law.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ALLIANCE FOR LONGEVITY INITIATIVES via NOVEL STRATEGIES (FKA) PRISM GROUP
2026 · third_quarter · Q3
Increased funding for longevity research at the National Institutes of Health
Directing the Food and Drug Administration to create a pathway for longevity treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCUBATE via NOVEL STRATEGIES (FKA) PRISM GROUP
2026 · third_quarter · Q3
Ensuring Pathways to Innovative Cures (EPIC) Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
GENEVANT SCIENCES, INC. via NOVEL STRATEGIES (FKA) PRISM GROUP
2026 · second_quarter · Q2
Matters pertaining to patent law.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENEVANT SCIENCES, INC. via NOVEL STRATEGIES (FKA) PRISM GROUP
2026 · second_quarter · RA
Matters pertaining to patent law
Matters pertaining to patent law
GENEVANT SCIENCES, INC. via NOVEL STRATEGIES (FKA) PRISM GROUP
2026 · second_quarter · RA
Matters pertaining to patent law
Matters pertaining to patent law
THE ALLIANCE FOR LONGEVITY INITIATIVES via NOVEL STRATEGIES (FKA) PRISM GROUP
2026 · second_quarter · Q2
Increased funding for longevity research at the National Institutes of Health
Directing the Food and Drug Administration to create a pathway for longevity treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCUBATE via NOVEL STRATEGIES (FKA) PRISM GROUP
2026 · second_quarter · Q2
Ensuring Pathways to Innovative Cures (EPIC) Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
INCUBATE via NOVEL STRATEGIES (FKA) PRISM GROUP
2026 · first_quarter · Q1
Ensuring Pathways to Innovative Cures (EPIC) Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
THE ALLIANCE FOR LONGEVITY INITIATIVES via NOVEL STRATEGIES (FKA) PRISM GROUP
2026 · first_quarter · Q1
Directing the Food and Drug Administration to create a pathway for longevity treatment. Reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Institutes of Health.
Increased funding for longevity research at the National Institutes of Health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCUBATE via NOVEL STRATEGIES (FKA) PRISM GROUP
2025 · fourth_quarter · Q4
Ensuring Pathways to Innovative Cures (EPIC) Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
THE ALLIANCE FOR LONGEVITY INITIATIVES via NOVEL STRATEGIES (FKA) PRISM GROUP
2025 · fourth_quarter · Q4
Directing the Food and Drug Administration to create a pathway for longevity treatment. Reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Institutes of Health.
Increased funding for longevity research at the National Institutes of Health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCUBATE via NOVEL STRATEGIES (FKA) PRISM GROUP
2025 · third_quarter · Q3
Ensuring Pathways to Innovative Cures (EPIC) Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
THE ALLIANCE FOR LONGEVITY INITIATIVES via NOVEL STRATEGIES (FKA) PRISM GROUP
2025 · third_quarter · Q3
Directing the Food and Drug Administration to create a pathway for longevity treatment. Reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Institutes of Health.
Increased funding for longevity research at the National Institutes of Health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ALLIANCE FOR LONGEVITY INITIATIVES via NOVEL STRATEGIES (FKA) PRISM GROUP
2025 · second_quarter · Q2
Directing the Food and Drug Administration to create a pathway for longevity treatment. Reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Institutes of Health.
Increased funding for longevity research at the National Institutes of Health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCUBATE via NOVEL STRATEGIES (FKA) PRISM GROUP
2025 · second_quarter · Q2
Ensuring Pathways to Innovative Cures (EPIC) Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, White House Office
THE ALLIANCE FOR LONGEVITY INITIATIVES via NOVEL STRATEGIES (FKA) PRISM GROUP
2025 · first_quarter · Q1
Directing the Food and Drug Administration to create a pathway for longevity treatment. Reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Institutes of Health.
Increased funding for longevity research at the National Institutes of Health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ALLIANCE FOR LONGEVITY INITIATIVES via NOVEL STRATEGIES (FKA) PRISM GROUP
2025 · first_quarter · RR
Creating a dedicated regulatory pathway for longevity therapeutics. Increasing allocations at NIH for aging research.